Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
BIOA
↓ PDF (Pro)BioAge Labs Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNASDAQ
$16.29
-1.99%today
MKT CAP
$820M
-1.6% · 1Y
Earnings History
-57.3%
-9.0%
-7.7%
+17.1%
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Analyst Targets
Current price
$16.29
Low
$23.00
Analyst Mean
$53.33
High
$73.00
6 analystsBuy
Full Financials
Trailing P/E-
Forward P/E-
EV/EBITDA-5.6x
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ-9.9%
5y Revenue CAGR-
5y Earnings CAGR-
Gross Margin0.0%
Operating Margin-923.4%
Net Margin0.0%
ROE-27.1%
Debt / Equity2.04x
Free Cash Flow$-54,844,124
Insider Ownership2.4%
Institutional Ownership61.0%
Short % of Float4.47%
Days to Cover3.3d
1 Week-7.3%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A | Chief Financial Officer | Conversion | 3,542 | $4.38 | $0.02M | 2026-04-23 |
| RUBIN PAUL D | Officer | Sale | 8,820 | $17.81 | $0.16M | 2026-04-01 |
| RUBIN PAUL D | Officer | Conversion | 8,820 | $4.11 | $0.04M | 2026-04-01 |
| RUBIN PAUL D | Officer | Sale | 7,433 | $20.30 | $0.15M | 2026-03-02 |
| RUBIN PAUL D | Officer | Conversion | 7,433 | $4.11 | $0.04M | 2026-03-02 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| a16z Capital Management, L.L.C. | institution | 7.28% | $0.06B | +0.00% | 2025-12-31 |
| Sofinnova Investments, Inc. | institution | 5.17% | $0.04B | +0.00% | 2025-12-31 |
| Cormorant Asset Management, LP | institution | 4.60% | $0.04B | -4.67% | 2025-12-31 |
| Octagon Capital Advisors LP | institution | 3.60% | $0.03B | +100.00% | 2025-12-31 |
| Blackrock Inc. | institution | 3.44% | $0.03B | +19.37% | 2025-12-31 |
| Vanguard Group Inc | institution | 3.19% | $0.03B | -14.32% | 2025-12-31 |
| Adage Capital Partners GP L.L.C. | institution | 2.36% | $0.02B | +100.00% | 2025-12-31 |
| Orbimed Advisors LLC. | institution | 1.78% | $0.01B | +0.00% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 1.78% | $0.01B | -31.63% | 2025-12-31 |
| Sands Capital Alternatives, LLC | institution | 1.77% | $0.01B | +0.00% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 1.64% | $0.01B | +26.13% | 2026-03-31 |
| Pivotal bioVenture Partners Investment Advisor, LLC | institution | 1.47% | $0.01B | +0.00% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 0.65% | $0.01B | +46.31% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 Value ETF | fund | 0.58% | $0.00B | +24.47% | 2026-03-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.52% | $0.00B | +1.35% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | fund | 0.48% | $0.00B | +100.00% | 2026-03-31 |
| iShares Trust-iShares Biotechnology ETF | fund | 0.48% | $0.00B | -2.34% | 2026-03-31 |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap ETF | fund | 0.36% | $0.00B | -10.29% | 2026-04-30 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | fund | 0.31% | $0.00B | -0.36% | 2026-02-28 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | fund | 0.28% | $0.00B | +1.07% | 2026-02-28 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| ETON | $833M | 60 | - | 16.4 | - | - | - | - | 0.00% |
| ESPR | $806M | 80 | - | 12.9 | - | - | - | - | 0.00% |
| PCRX | $937M | 58 | 193.0 | 7.0 | - | - | - | - | 0.00% |
| CRON | $990M | 5 | - | - | - | - | - | - | 0.00% |
| AMPH | $1.1B | 100 | 11.8 | 6.9 | - | - | - | - | 0.00% |
| XERS | $1.1B | 60 | 94.7 | 17.0 | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for BIOA.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.